Akero Therapeutics Inc.

26.41-0.6000-2.22%Vol 259.79K1Y Perf 26.35%
Apr 13th, 2021 16:00 DELAYED
BID26.36 ASK26.42
Open27.45 Previous Close27.01
Pre-Market- After-Market-
 - -  - -%
Target Price
59.43 
Analyst Rating
Strong Buy 1.00
Potential %
125.03 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap918.28M 
Earnings Rating
Price Range Ratio 52W %
35.31 
Earnings Date
12th May 2021

Today's Price Range

26.1127.48

52W Range

18.3641.16

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.78%
1 Month
-19.92%
3 Months
-8.46%
6 Months
-7.53%
1 Year
26.35%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AKRO26.41-0.6000-2.22
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.72-0.86-19.44
Q03 2020-0.48-0.63-31.25
Q02 2020-0.48-0.57-18.75
Q01 2020-0.60-0.4230.00
Q04 2019-0.59-0.556.78
Q03 2019-0.43-0.56-30.23
Q02 2019-0.36-2.21-513.89
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th May 2021
Estimated EPS Next Report-1.01
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume259.79K
Shares Outstanding34.77M
Trades Count2.96K
Dollar Volume6.91M
Avg. Volume293.85K
Avg. Weekly Volume224.02K
Avg. Monthly Volume319.99K
Avg. Quarterly Volume260.10K

Akero Therapeutics Inc. (NASDAQ: AKRO) stock closed at 26.41 per share at the end of the most recent trading day (a -2.22% change compared to the prior day closing price) with a volume of 259.79K shares and market capitalization of 918.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Akero Therapeutics Inc. CEO is Andrew Cheng.

The one-year performance of Akero Therapeutics Inc. stock is 26.35%, while year-to-date (YTD) performance is 2.36%. AKRO stock has a five-year performance of %. Its 52-week range is between 18.36 and 41.16, which gives AKRO stock a 52-week price range ratio of 35.31%

Akero Therapeutics Inc. currently has a PE ratio of -11.30, a price-to-book (PB) ratio of 3.80, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.39%, a ROC of -30.03% and a ROE of -39.72%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Akero Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.01 for the next earnings report. Akero Therapeutics Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Akero Therapeutics Inc. is Strong Buy (1), with a target price of $59.43, which is +125.03% compared to the current price. The earnings rating for Akero Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akero Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akero Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.84, ATR14 : 1.74, CCI20 : -119.67, Chaikin Money Flow : -0.20, MACD : -0.20, Money Flow Index : 12.55, ROC : -10.54, RSI : 54.69, STOCH (14,3) : 4.36, STOCH RSI : 0.50, UO : 37.06, Williams %R : -95.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akero Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

CEO: Andrew Cheng

Telephone: +1 650 487-6488

Address: 170 Harbor Way, South San Francisco 94080, CA, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

News

Stocktwits